For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

You are here

Publications

Found 45 results
Author Title [ Type(Desc)] Year
Filters: Author is C Nathan  [Clear All Filters]
Journal Article
Nathan C.  2017.  Kunkel Lecture: Fundamental immunodeficiency and its correction.. J Exp Med. 214(8):2175-2191.
Bryk R, Lima CD, Erdjument-Bromage H, Tempst P, Nathan C.  2002.  Metabolic enzymes of mycobacteria linked to antioxidant defense by a thioredoxin-like protein.. Science. 295(5557):1073-7.
Lin G, Chidawanyika T, Tsu C, Warrier T, Vaubourgeix J, Blackburn C, Gigstad K, Sintchak M, Dick L, Nathan C.  2013.  N,C-Capped dipeptides with selectivity for mycobacterial proteasome over human proteasomes: role of S3 and S1 binding pockets.. J Am Chem Soc. 135(27):9968-71.
Nathan C.  2006.  Neutrophils and immunity: challenges and opportunities.. Nat Rev Immunol. 6(3):173-82.
Nathan C, Nussenzweig M, Pulvirenti T.  2017.  The new face of JEM.. J Exp Med. 214(12):3467.
Warrier T, Kapilashrami K, Argyrou A, Ioerger TR, Little D, Murphy KC, Nandakumar M, Park S, Gold B, Mi J et al..  2016.  N-methylation of a bactericidal compound as a resistance mechanism in Mycobacterium tuberculosis.. Proc Natl Acad Sci U S A. 113(31):E4523-30.
Nathan C, Ding A.  2010.  Nonresolving inflammation.. Cell. 140(6):871-82.
Gold B, Smith R, Nguyen Q, Roberts J, Ling Y, Quezada LLopez, Somersan S, Warrier T, Little D, Pingle M et al..  2016.  Novel Cephalosporins Selectively Active on Nonreplicating Mycobacterium tuberculosis.. J Med Chem. 59(13):6027-44.
Van Voorhis WC, Adams JH, Adelfio R, Ahyong V, Akabas MH, Alano P, Alday A, Resto YAlemán, Alsibaee A, Alzualde A et al..  2016.  Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond.. PLoS Pathog. 12(7):e1005763.
Bryk R, Griffin P, Nathan C.  2000.  Peroxynitrite reductase activity of bacterial peroxiredoxins.. Nature. 407(6801):211-5.
Nathan C.  2002.  Points of control in inflammation.. Nature. 420(6917):846-52.
Totaro KA, Barthelme D, Simpson PT, Jiang X, Lin G, Nathan C, Sauer RT, Sello JK.  2017.  Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome.. ACS Infect Dis. 3(2):176-181.
Lupoli TJ, Fay A, Adura C, Glickman MS, Nathan C.  2016.  Reconstitution of a Mycobacterium tuberculosis proteostasis network highlights essential cofactor interactions with chaperone DnaK.. Proc Natl Acad Sci U S A. 113(49):E7947-E7956.
Saito K, Warrier T, Somersan-Karakaya S, Kaminski L, Mi J, Jiang X, Park S, Shigyo K, Gold B, Roberts J et al..  2017.  Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations.. Proc Natl Acad Sci U S A. 114(24):E4832-E4840.
Mosior J, Bourland R, Soma S, Nathan C, Sacchettini J.  2019.  Structural insights into phosphopantetheinyl hydrolase PptH from Mycobacterium tuberculosis.. Protein Sci.
Santos Rde Luna Al, Bai L, Singh PK, Murakami N, Fan H, Zhan W, Zhu Y, Jiang X, Zhang K, Assker JPierre et al..  2017.  Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes.. Nat Commun. 8(1):1692.
Nathan C.  2009.  Taming tuberculosis: a challenge for science and society.. Cell Host Microbe. 5(3):220-4.
Gold B, Nathan C.  2017.  Targeting Phenotypically Tolerant Mycobacterium tuberculosis.. Microbiol Spectr. 5(1)
Nathan C, Barry CE.  2015.  TB drug development: immunology at the table.. Immunol Rev. 264(1):308-18.
Nathan C.  2015.  What can immunology contribute to the control of the world's leading cause of death from bacterial infection? Immunol Rev. 264(1):2-5.